Comparative study demonstrates reduced donation time and target deviation in apheresis collections, indicating improved efficiency for pathogen-reduced platelets.
Background: Platelet concentrates from apheresis donations are indispensable in transfusion medicine. Integration of pathogen reduction (PR) technologies into platelet manufacturing requires adjustment of apheresis devices to ensure consistent platelet yields while minimizing donation time. We investigated the suitability of Sysmex XN1000 (Sysmex Corporation, Kobe, Japan) in blood bank mode (BBM) for measuring platelet concentrates to optimize the yield-scaling factor (YSF) of apheresis devices, thereby standardizing target yields and reducing donation time. Methods: We compared measurements with the Sysmex XN530 and XN1000 BBM and evaluated three Trima Accel (Terumo, Tokyo, Japan) YSF setups (YSF 0.90/XN530, YSF 0.90/XN1000, and YSF 1.05/XN1000). Differences in yield deviation and donation time were assessed using linear mixed-effects models adjusted for target yield with robust SEs. Results: platelets/unit (95% CI 0.24-0.45 and 0.01-0.47, respectively) in DS collections. Compared with YSF 0.90/XN530, YSF 1.05/XN1000 reduced the donation time by 8.09 min (6.93-9.26) and 9.88 min (6.81-12.94) for LV and DS collections, respectively. Conclusions: YSF 0.90/XN1000 and YSF 1.05/XN1000 reduced yield deviation and donation time than did YSF 0.90/XN530, supporting the use of XN1000 BBM to calibrate Trima Accel apheresis devices and can help in standardizing target yields while reducing donation time in PR.
No takes yet. Share an insight, caveat, or question.
Amato et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: